#ASCO22: Following back-to-back TIGIT bombs, Roche offers insight into first PhIII trial fail

Lei Lei Wu

News Reporter

Roche’s Genentech suffered two consecutive Phase III fails for tiragolumab, the earliest in a series of anti-TIGIT drugs from Big Pharmas hoping to usher in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASCO22: Following back-to-back TIGIT bombs, Roche offers insight into first PhIII trial fail

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

#AS­CO22: Fol­low­ing back-to-back TIG­IT bombs, Roche of­fers in­sight in­to first PhI­II tri­al fail

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

#ASCO22: Following back-to-back TIGIT bombs, Roche offers insight into first PhIII trial fail